A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals

Pharmacoepidemiology and Drug Safety

Volumn 9, Issue 1, 2000, Pages 49-53

  McCarthy, W F ^a,b   Gable, J ^b   Lawrence, J ^b   Thompson, M ^b  

^a AIDS Research Consortium of Atlanta ^*  (United States)

^b AIDS Research Consortium of Atlanta   (United States)

Author keywords

d4T; ddI; HIV 1; Hydroxyurea; Peripheral neuropathy

Indexed keywords

ANTIRETROVIRUS AGENT; DAPSONE; DIDANOSINE; HYDROXYUREA; ISONIAZID; STAVUDINE; ZALCITABINE;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK;

EID: 0034057399     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(200001/02)9:1<49::AID-PDS465>3.0.CO;2-C     Document Type: Article

References (16)

1. American Foundation for AIDS Research. AIDS/HIV Treatment Directory 1998; 9(2): 45-47, 49-50.
2. Donehower R. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19(Suppl. 9): 11-19.
3. Gao W, Cara A, Gallo RC, Lori F. Low levels of dideoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. PNAS 1993; 90: 8925-8928.
4. Lori F, Malyykh A, Cara A et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266: 801-805.
5. Biron F, Lucht F, Peyramond D et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquired Imm Defic Syndr Hum Retrovirol 1995; 10: 36-40.
6. Vila J, Biron F, Nugier F et al. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996; 348: 203-204.
7. Rutschmann OT, Opravil M, Iten A et al. Placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS 1998; 12: F71-F79.
8. Palmer S, Cox S. Increased activation of the combination of 3'-azido-3' deoxythymadine and 2′-deoxy-3′ thiacytidine in the presence of hydroxyurea. Antimicrob Ag Chemother 1997; 41: 460-464.
9. American Foundation for AIDS Research. AIDS/HIV Treatment Directory 1998; 9(2): 46, 50.
10. American Foundation for AIDS Research. AIDS/HIV Treatment Directory 1998; 9(2): 46, 142.
11. Farizo KM, Buehler JW, Chamberland ME et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267: 1798-1805.
12. Kleinbaum DG. Logistic Regression. Springer: New York, NY, 1994; 194-198.
13. Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley & Sons, Inc.: New York, NY, 1989; 87.
14. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41(No. RR-17): 16-19.
15. Ewald GA, McKenzie CR. Manual of Medical Therapeutics, 28th edn. Little, Brown and Company: Boston, MA, 1995; 291.
16. Sande MA, Volberding PA. The Medical Management of AIDS, 6th edn. W. B. Saunders Company: Philadelphia, PA, 1999; 231-232.